Skip to main content

Table 1 Univariate analysis (Kaplan-Meier method) of possible factors associated with the development of brain metastasis of non-metastatic breast cancer patients at diagnosis

From: Identification of breast cancer patients with a high risk of developing brain metastases: a single-institutional retrospective analysis

Characteristics n % 3-year brain metastasis-free survival -95% CI +95% CI p-value*
Age (years)       0.10
  ≤35 36 10.3 0.87 0.74 1.00  
  >35 316 89.7 0.95 0.92 0.99  
Menopausal status       0.33
  Pre-menopausal 165 47.0 0.95 0.91 0.99  
  Post-menopausal 187 53.0 0.94 0.88 0.99  
Body Mass Index       0.88
  <25 60 17.1 0.95 0.88 1.00  
  25-29 118 33.6 0.96 0.91 1.00  
  ≥30 174 49.3 0.93 0.88 0.99  
T stage       0.19
  0-2 200 56.7 0.96 0.92 1.00  
  3-4 152 43.3 0.93 0.87 0.99  
N stage       0.19
  0-1 253 72.1 0.95 0.91 0.99  
  2-3 99 27.9 0.93 0.88 0.99  
Stage       0.10
  Localized 133 37.9 0.95 0.89 1.00  
  Regional 219 62.1 0.94 0.90 0.98  
ER status       <0.001
  Positive 243 69.2 0.99 0.98 1.00  
  Negative 109 30.8 0.84 0.74 0.94  
PR status       0.01
  Positive 216 61.5 0.99 0.96 1.00  
  Negative 136 38.5 0.88 0.80 0.95  
HER2 status       0.31
  Positive 88 25.1 0.98 0.95 1.00  
  Negative 264 74.9 0.93 0.89 0.98  
Tumor subtype       <0.001
  Triple negative 63 17.7 0.78 0.64 0.93  
  Her2 overexpressing 35 10.0 0.96 0.88 1.00  
  Luminal A 201 57.3 0.98 0.95 1.00  
  Luminal B 53 15.1 1.00 1.00 1.00  
  1. Abbreviation: 95% CI = 95% confidence interval of the 3-year brain metastasis-free survival; * = log rank test.